anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

131,041-131,100 of 319,975

filter-aware
242
The slide uses a quote-based argument to challenge the company's stated quality control rationale.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
243
The slide uses direct quotes to highlight operational failures and lack of training in the field.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
244
The slide uses a narrative structure to expose operational risks and employee dissatisfaction.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
245
The slide uses a Q&A format to highlight alleged safety violations and hospital staff complaints.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
246
The slide uses a narrative format to expose operational failures and potential ethical/regulatory concerns regarding TransMedics' high-volume users.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
247
The slide uses direct quotes to highlight operational risks and potential regulatory/ethical violations regarding the use of OCS specialists.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
248
The slide uses a Q&A transcript format to substantiate claims of poor management and safety negligence.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
249
TransMedics (TMDX)TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
250
The slide uses strong, emotive language to frame the company's leadership as the primary antagonist.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
251
The slide uses highlighted text to emphasize key grievances (dishonesty, forced bundling, anger).TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
252
The slide uses direct quotes from KOLs to build a negative narrative around the company's business ethics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
253
The slide uses highlighted text to emphasize key quotes from former executives regarding the CEO's professional conduct.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
254
The slide uses direct quotes from former employees and industry contacts to build a negative narrative around the CEO's personality and professional standing.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
255
The slide uses a combination of summary text and a direct quote to highlight unethical business practices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
256
The slide uses a Q&A transcript format to substantiate a serious allegation of unethical business practices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
257
The slide uses verbatim interview transcripts to substantiate claims of extortion and unprofessional conduct by specific named executives.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
258
The slide uses a Q&A transcript format to highlight negative sentiment regarding company culture and sales practices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
259
The slide uses a Q&A format to document allegations of unethical sales pressure by a specific individual (Magdy Attia) at TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
260
The slide uses a Q&A format to build a case against the company's business practices.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
261
The slide uses a Q&A format to highlight potential malpractice and coercion.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
262
The slide presents a narrative of a specific medical failure involving a necrotic liver, alleging that TransMedics may be concealing damage from receiving centers.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
263
The slide uses a Q&A format to highlight a specific allegation of corporate dishonesty.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
264
The slide uses a Q&A format to highlight a perceived cover-up by the company regarding device performance.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
265
The slide uses a quote to highlight a perceived lack of transparency by the company.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
266
The slide uses direct quotes to characterize the CEO as 'arrogant' and the company's behavior as 'extortion' and 'aggressive'.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
267
The slide uses a combination of summary text and direct interview transcripts to build a case of corporate misconduct.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
268
The slide presents a narrative of professional misconduct and coercion within an organ procurement organization.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
269
This appears to be a narrative slide from a research note or report, focusing on churn.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
270
The slide uses anecdotal evidence from a 'prominent surgeon' to support a bearish thesis on TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
271
The slide uses direct quotes from surgeons to build a narrative of financial unviability and institutional pushback against the product.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
272
The slide uses a Q&A format to directly contradict claims made by the TransMedics CEO regarding reimbursement pass-through.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
273
The slide uses direct quotes to build a narrative of customer churn and institutional resistance.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
274
The slide uses Q&A transcripts to highlight a shift away from OCS technology in high-volume transplant centers.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
275
The slide uses a 'villain critique' style to highlight negative sentiment from industry insiders regarding TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
276
The slide uses a Q&A format to highlight a specific expert's negative sentiment toward TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
277
The slide uses direct quotes from a high-volume TransMedics user to illustrate market vulnerability and the shift toward competitors offering more autonomy.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
278
The slide uses a Q&A format to build a narrative of market abandonment.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
279
The slide uses direct quotes from an UCSF administrator to build a case against TransMedics' long-term viability at the institution.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
280
The slide uses highlighted text to emphasize key negative sentiment regarding TransMedics' sustainability and market position.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
281
This slide serves as a highly critical, accusatory statement against the subject company.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
282
The slide uses a testimonial from a transplant surgeon to support a bearish thesis on the company's market position.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
283
The slide uses direct quotes from KOLs to frame the company's technology as a commoditized, overpriced solution with no clinical advantage over traditional cold storage.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
284
The slide uses direct quotes from a KOL to undermine the company's market position.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
285
The slide uses a 'villain critique' approach by aggregating expert opinions to undermine the company's value proposition.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
286
The slide uses a Q&A format to highlight the gap between the device's intended utility and real-world clinical experience.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
287
The slide uses highlighted text to emphasize key negative findings regarding the OCS technology's performance metrics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
288
The slide uses a 'before-after' style comparison between a conceptual timeline and actual competitor hardware.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
289
The slide uses expert quotes to undermine the competitive moat of TransMedics by comparing it to existing, commoditized kidney perfusion technology.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
290
The slide uses a Q&A format to highlight the perceived lack of value proposition for the OCS Lung product.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
291
The slide uses direct quotes from a surgeon to undermine the company's value proposition.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
292
The slide uses highlighted text to emphasize key negative claims from a surgeon.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
293
The slide uses expert testimonials to argue that the TransMedics device is 'fatally flawed' because it does not allow for functional assessment under load.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
294
The slide uses direct quotes from surgeons to validate the market share shift thesis.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
295
The slide uses a direct quote from a surgeon to undermine the credibility and clinical utility of the TransMedics OCS device.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
296
The slide uses a direct quote from an expert to undermine the value proposition of the TransMedics device.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
297
The slide uses a quote-heavy structure to undermine the investment thesis for TransMedics (TMDX).TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
298
The slide uses a Q&A transcript format to highlight negative expert sentiment.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
299
The slide presents a synthesis of expert commentary followed by verbatim Q&A excerpts highlighting the 'last resort' nature of the current service and the future growth thesis.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
300
The slide uses direct quotes from surgeons and an ex-employee to build a case against the viability of the NOP service for heart transplants.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
301
The slide uses direct quotes and Q&A transcripts to undermine the clinical value proposition of the TransMedics device.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit